Syantra Featured in BetaKit Ahead of Commercialization of their Onco-ID Breast Cancer Test

Syantra has been featured in Betakit ahead of the commercialization of their Onco-ID breast cancer blood test expected this summer. This revolutionary test is an early detection screening tool. It works by detecting the body’s immune response to cancer, unlike current testing which looks for specific cancer cells. Syantra’s blood test has also been shown to be more effective than mammograms for women with dense breast tissue. 

And, Syantra plans to release updated clinical trial data in Q2 2026. 

Read more about the latest from Syantra in the BetaKit article here. 

Thanks BetaKit for the coverage!

‍